The human epidermal growth factor receptor (EGFR) gene in European patients with advanced colorectal cancer harbors infrequent mutations in its tyrosine kinase domain by Metzger, Brigitte et al.
RESEARCH ARTICLE Open Access
The human epidermal growth factor receptor
(EGFR) gene in European patients with advanced
colorectal cancer harbors infrequent mutations in
its tyrosine kinase domain
Brigitte Metzger
1, Laetitia Chambeau
1, Dominique Y Begon
2, Carlo Faber
3, Jacques Kayser
3, Guy Berchem
4,
Marc Pauly
1, Jacques Boniver
2, Philippe Delvenne
2, Mario Dicato
1,4 and Thomas Wenner
1*
Abstract
Background: The epidermal growth factor receptor (EGFR), a member of the ErbB family of receptors, is a
transmembrane tyrosine kinase (TK) activated by the binding of extracellular ligands of the EGF-family and involved
in triggering the MAPK signaling pathway, which leads to cell proliferation. Mutations in the EGFR tyrosine kinase
domain are frequent in non-small-cell lung cancer (NSCLC). However, to date, only very few, mainly non-European,
studies have reported rare EGFR mutations in colorectal cancer (CRC).
Methods: We screened 236 clinical tumor samples from European patients with advanced CRC by direct DNA
sequencing to detect potential, as yet unknown mutations, in the EGFR gene exons 18 to 21, mainly covering the
EGFR TK catalytic domain.
Results: EGFR sequences showed somatic missense mutations in exons 18 and 20 at a frequency of 2.1% and 0.4%
respectively. Somatic SNPs were also found in exons 20 and 21 at a frequency of about 3.1% and 0.4% respectively.
Of these mutations, four have not yet been described elsewhere.
Conclusions: These mutation frequencies are higher than in a similarly sized population characterized by Barber
and colleagues, but still too low to account for a major role played by the EGFR gene in CRC.
Background
The epidermal growth factor receptor (EGFR) is a cell
surface receptor belonging to the ErbB family of recep-
tors, a family of four tyrosine kinase receptors, EGFR
(ErbB-1), HER2/c-neu (ErbB-2), Her3 (ErbB-3) and
Her4 (ErbB-4). These tyrosine kinases are involved in
various aspects of cell growth and survival and have
been implicated in the initiation and progression of sev-
eral types of human malignancies. EGFR is involved in
cell growth control through its role in the mitogen-acti-
vating-protein-kinase (MAPK) pathway. Therefore, over-
expression or mutation of EGFR may be responsible for
the constitutive activation of the pathway which these
receptors control[1]. In colorectal cancer (CRC), the
EGFR gene has been found to be over expressed in
more than 80% of tumors and is significantly associated
with TNM stage T3[2]. Hence, EGFR might be involved
in the development of colorectal cancer and has now
been validated as a clinically relevant target. At present,
two different monoclonal antibodies raised against the
extracellular part of the EGFR receptor are in use in a
clinical setting (Cetuximab and Panitumumab). Both of
these monoclonal antibodies bind to the extracellular
domain of the EGFR preventing its activation but,
Cetuximab and Panitumumab have single-agent
response rates in the region of only 10%[3,4]. K-ras
mutational status could in part explain this poor out-
come as mutation in the K-ras gene would activate the
EGFR pathway whatever the activation of EGFR receptor
is activated or blocked. However 40% to 70% of patients
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these monoclonal antibodies[5-7]. This might be
explained by the occurrence of mutation in the same
pathway downstream of K-ras, as B-raf for example, or
by the variation of the EGFR receptor copy number
[8-10]. This might also be explained by the occurrence
of mutations in the EGFR g e n ea ss h o w ni nn o n - s m a l l -
cell lung cancer (NSCLC), where mutations in exons
18-21 coding for the tyrosine kinase domain are fre-
quent (10-50%)[11]. These mutations, however, are gen-
erally related to an increased sensitivity to EGFR
inhibitors, which might not be the case in CRC.
There are only a few reports of mutations in the EGFR
gene in colorectal tumors and all of these used sequen-
cing after gene amplification. The first report focused
on only 31 cases from Milan (Italy) and is the only Eur-
opean study[12]. Of these 31 cases, only one showed a
mutation. The second study focused on 33 cases and
was performed on Japanese patients from Beppu[13]. Of
these 33 cases, ten were detected as having mutations in
the EGFR gene. The third focused on 101 Chinese
(Shangaï) patients and the authors described only 2
mutations[14]. The last study was conducted by Barber
et al.,[15] in Baltimore USA, where only one mutation
in 293 patients was characterized.
Since EGFR mutations in NSCLC have a substantially
higher frequency in East Asians than in other ethnicities,
a relationship between EGFR mutation frequency and
ethnicity has been established[16]. We studied a large
cohort of a European population in order to investigate
the frequency of occurrence of mutations in the EGFR
gene in a European context and to determine if these
mutation occur as frequently as in the American popu-
lation. We also determined the somatic nature of the
mutation by using the corresponding patient’s blood
DNA as the control.
Methods
Patients
Two hundred and thirty-six tumor samples were col-
lected between 2002 and 2007, were obtained from
patients with CRC with the agreement of the Luxem-
bourg Ethics Committee and informed consent were
obtained from all participants. All patients were of Eur-
opean ethnicity. The samples had a histological stage
equal to or greater than pT1.
Clinical tumor samples and non-tumor control samples
Colorectal tumor samples were isolated during surgical
resection and, in order to obtain more than 80% of the
cancer tissue, a small part of the middle of the tumor was
rapidly frozen by the clinician in liquid nitrogen and
stored at -80°C until genomic DNA preparation. As a
non-tumor tissue control, whole leukocyte samples were
collected from the same patients in vacutainers/EDTA
(Becton Dickinson, Rutherford, New Jersey, USA) and
extraction was carried out using NH4Cl treatment. These
control cells were used to determine whether these muta-
tions were germline or somatic for each mutation found
(i.e. silent or missense). Hence, each time we found a
mutation in an exon, the corresponding leukocyte DNA
was sequenced in both directions in the same exon.
Genomic DNA preparation
Cellular genomic DNA was extracted from roughly 25
mg tumor tissue or non-tumor leukocyte control sam-
ples using the DNeasy Blood & Tissue kit (Qiagen,
Westburg, Leusden, the Netherlands) and DNA concen-
trations were checked using a nanodrop ND1000 appa-
ratus (ThermoFisher, Aalst, Belgium) according to the
manufacturer’s instructions.
PCR amplification
Specific PCR primers (Eurogentec, Seraing, Belgium) for
the amplification of the DNA regions covering exons 18,
19, 20 and 21, respectively, of the human EGFR gene
tyrosine kinase domain were designed according to [1]
(Table 1).
PCR amplification was performed using the AmpliTaq
Gold
® DNA polymerase (Applied Biosystems, Halle, Bel-
gium) according to the manufacturer’sp r o t o c o lu s i n g
1 0 0n go fg e n o m i cD N Ai na nE p p e n d o r fM a s t e r c y c l e r
(Eppendorf, Fisher Scientific, Aalst, Belgium). The PCR
program was set up with a denaturizing step of 10 min
at 95°C followed by 30 repetitions of the following
sequence: 95°C, 1 min; annealing temperature according
to the primer used (Table 1), 1 min; 72°C, 1 min; and a
final elongation step of 10 min. The resulting PCR pro-
ducts were checked on 2% agarose gel electrophoresis
and purified using the ExoSAP-IT
® purification method
(USB Affymetrix, Cleveland, USA).
KRAS mutations located within codons 12 and 13
were characterized by direct sequencing according to
the conditions published in [17].
Direct DNA sequencing
Once purified, the PCR products were analyzed by
direct automatic PCR-assisted DNA dideoxynucleotide
sequencing according to the manufacturer’sp r o t o c o l
using the oligonucleotides previously described (Big Dye
Terminator V3.1, Applied Biosystems, Halle, Belgium).
Analysis of the purified sequenced products was per-
formed on a 3130 Genetic Analyzer (Applied Biosys-
tems, Halle, Belgium). Where there was the possibility
of a mutation, sequencing was repeated at least once in
the antisense direction for confirmation as well as on a
new PCR product and in the corresponding leukocyte
control.
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DNA sequence data were examined for potential point
mutations, deletions and insertions using the SeqScape
software version 2.5 (Applied Biosystems, Halle,
Belgium).
Results
Cellular genomic DNA was extracted from clinical
tumor tissue, adenoma-carcinomas, or from leukocytes
as control samples, from 236 European CRC patients in
Luxembourg. Single nucleotide polymorphisms (SNP’s)
and mutations were detected and analyzed using the
EGFR gene card website, the cosmic database and the
EGFR database.
DNA regions covering exons 18, 19, 20 and 21 of the
human EGFR gene encompassing mainly the tyrosine
kinase domain were then amplified using PCR, and
directly sequenced. Missense mutations arose at a fre-
quency of 2.1%, 0%, 0.4% and 0.4% in exons 18 to 21
respectively whereas these samples showed an overall
frequency of mutation of 2.6%, 0.5%, 0.8%, and 3.8% in
exons 18 to 21 respectively. Among these mutations, we
were able to distinguish those already described from
non described missense mutations (affecting protein
sequence) and silent point mutations (mutations affect-
ing DNA sequences without affecting protein sequence).
Moreover, each time a mutation was characterized in an
exon, it was confirmed by a reverse sequencing in the
same PCR product and on a new one (both ways) and
the same exon was sequenced in the blood DNA of the
patient where this mutation was found (both ways).
Sometimes we ran out of colorectal tissues from some
patients and were therefore unable to sequence 236
samples for all the four exons. We were, nevertheless,
able to sequence 188, 221, 227 and 236 samples for
exons 18, 19, 20 and 21, respectively.
In exon 18, missense point mutations were present
with a frequency of only 2.1% (4 out of 188 cases deter-
mined (Figure 1 and Table 2). Only one mutation had
already been described and this affected codon 712
(TTC to TCC transition, F712S). The three remaining
mutations had not yet been described in CRC nor in
other cancers according to the EGFR databases and
these affected codons 707 (TTG to TCG transition,
L707S), 710 (ACT to GCT transition, T710A) and 711
(GAA to GTT double transversion Q711V). The mis-
sense mutations were all somatic, since none was found
in the non-tumor control tissue.
The last mutation found in exon 18 was a silent germ-
inal point mutation and corresponds to a SNP, at codon
725 (ACGt oA C A transition, Y725Y) in one patient
(Table 2). Nucleotide positions mutated are detailed in
table 2.
In exon 19, only one mutation was detected out of
221 samples determined (frequency 0.5%, Table 2). This
mutation has yet not been described and might be a
new SNP since it consisted of another silent germline
point mutation found at codon 742 (GTCt oG T T tran-
sition, V742V).
In exon 20, two already described missense mutations
out of 225 determined samples (frequency 0.8%) were
characterized, one somatic mutation affecting codon 795
(TTC to TCC transition, F795S) and one germinal
mutation in codon 796 (GGC to AGC transition,
G796S). We also detected an already described SNP,
silent point mutation in codon 787, leading to a G to A
transition (CAG-CAA - Q787Q, unchanged), in 186 of
the 225 tumors analyzed (frequency 82.7%, 11 undeter-
mined). This SNP was either homozygous (93 cases,
41.3%) or heterozygous (G/A, 93 cases, 41.3%, Figure 1,
T a b l e3 ) .T h eS N Pw a sc o n s i dered heterozygous when
an electropherogram showed a superimposition of the
signals corresponding to G and A at roughly half the
intensity of the one obtained in homozygous sequences.
These silent point mutations were nearly all germinal as
91 heterozygous mutations and 92 homozygous muta-
tions were found both in tumors and in patient leuko-
cyte DNA (Table 3). There were only 3 cases where a
wild type sequence was found in leukocytes and had
mutated in tumors (2 heterozygous and 1 homozygous)
and surprisingly, 4 patients showed a mutated EGFR in
their leukocyte DNA but a wild type sequence in their
tumors (2 heterozygous, 2 homozygous). In order to
check whether this silent point mutation was more fre-
quently found in patients suffering from the disease, we
sequenced DNA from the leukocytes of healthy volun-
teers. A similar frequency of occurrence of this silent
point mutation was found, as 56 out of 61 controls
Table 1 Sequences of primers used to amplify and sequence EGFR exons 18 to 21
Exon Sequence 5’®3’ Tm (°C)
18 for CAAATGAGCTGGCAAGTGCCGTGTC rev GAGTTTCCCAAACACTCAGTGAAAC 58
19 for GCAATATCAGCCTTAGGTGCGGCTC rev CATAGAAAGTGAACATTTAGGATGTG 67
20 for CCATGAGTACGTATTTTGAAACTC rev CATATCCCCATGGCAAACTCTTGC 58
21 for CTAACGTTCGCCAGCCATAAGTCC rev GCTGCGAGCTCACCCAGAATGTCTGG 67
The annealing temperature is shown. For and rev are primers forward and reverse respectively according to the gene transcription orientation. Forward primers
were used to sequence all PCR products and reverse primers to confirm the presence of mutation.
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(34 heterozygotes and 22 homozygotes).
Finally, we characterized a still non described missense
mutation at codon 847 (ACA to AGA transversion, T847R,
frequency 1 out of 236 (0.4%) in exon 21. This mutation
was germinal as the same mutation was found in the leuko-
cytes of this patient. Moreover, an already described silent
SNP was found in 8 patients out of 236 tumors analyzed at
WT
Mutation T710 A
WT
Mutation L707S
A.
B.
Figure 1 Comparison between wild type and mutant electropherograms in A and B showing two novel mutations in exon 18 of the
EGFR gene.
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mutations were germline and one somatic, the remaining
mutation was undetermined (not sequenced).
Discussion
To summarize, missense mutations arose at a frequency
of 2.1%, 0%, 0.4% and 0.4% in exons 18 to 21 respectively
whereas these samples showed an overall frequency of
mutation of 2.6%, 0.5%, 0.8%, and 3.8% in exons 18 to 21
respectively. This included silent point mutation except
for exon 20 where a frequent silent point mutation
(82.7%) was characterized. These frequencies are within
the range of those reported elsewhere, in terms of over-
all frequency of missense mutation occurrence in exons
18 to 21, 0.34 to 12% [10-13,15,18-20]. Hence, our cohort
may be representative of the disease.
Unlike in NSCLC, where such mutations occur at a
frequency of up to 45%[1,21], neither small in-frame
deletions, double mutations (silent and missense) nor
insertions were found. In addition, in the case of mis-
sense mutations, transitions (4 somatic 1 germline, see
Table 2) were far more frequent (71.43%, 5 out of 7)
than transversions. Moreover, 71.43% of these mutations
were somatic and therefore specific to the tumor
whereas the remaining mutations were germline, since
they were also found outside the tumor, namely in the
normal control tissue represented by leucocytes from
the same patient. Most of these germline mutations
were already known SNPs except in exon 19 (V742V)
which has not yet been described and might be a new
SNP, and in exon 20 (G796S) which might also be a
new SNP although this mutation has been described in
prostate cancer as tumor specific[22]. Most of these
mutations were located in exon 18 corresponding to the
ATP nucleotide binding loop of the EGFR tyrosine
kinase domain (codons 707, 710, 711 and 712, 57.14%, 4
out of 7), two were located in exon 20 (codons 795 and
796) and one in exon 21 at codon 847, corresponding to
the kinase activity loop. None was found in exon 19.
At least one silent point mutation was observed in
each exon (codons 725, 742, 787 and 836). These were
all germline, except in one tumor at codon 836, where
the mutation was not found in the leukocytes from the
patient.
Moreover, in this study, we found an already known
silent SNP in EGFR exon 20 (Q787Q) arising at a very
high frequency (186 out of 225 analyzed, 82.7%). This
silent mutation has already been described in several
cases of NSCL or head and neck squamous carcinoma
[23,24] but only once in CRC,[13] occurring less
frequently.
Our main objective was to check if EGFR mutation
frequency might explain the poor efficacy of the use of
monoclonal antibody raised against the extracellular
part of the EGFR receptor. As this may be partially
explained by the occurrence of mutation in K-ras gene
which led to the constitutive activation of the K-ras
pathway, downstream of the EGFR receptor, we tested
the K-ras mutational status of our patient harboring a
mutation in the EGFR gene (Table 2). The K-ras gene
has been found mutated in two cases (2 out of 17 cases,
Table 2 Mutations found in EGFR exons 18 to 21
Exon Frequency Mutation type Heredity K-ras
status
TTG to TCG (L707S) n2120
Ti
sw t
ACT to GCT (T710A) n2128
Ti
sw t
18 5/188
(2.6%)
GAA to GTT (E711V) n2132/
2133 Tv
sw t
TTC to TCC (F712S) n2135 Ti s wt
ACG to ACA (T725T) n2175 Ti gw t
19 1/221
(0.5%)
GTC to GTT (V742V) n2226
Ti
gw t
TTC to TCC (F795S) n2384 Ti s wt
20 2/227
(0.8%)
GGC to AGC (G796S) n2386
Ti
gW t
CGC to CGT (R836R) n2508 Ti g M (13)
CGC to CGT (R836R) n2508 Ti gw t
CGC to CGT (R836R) n2508 Ti gw t
CGC to CGT (R836R) n2508 Ti gw t
21 9/236
(3.8%)
CGC to CGT (R836R) n2508 Ti gw t
CGC to CGT (R836R) n2508 Ti gw t
CGC to CGT (R836R) n2508 Ti s M (12)
CGC to CGT (R836R) n2508 Ti nd wt
ACA to AGA (T847R) n2540
Tv
gW t
Frequency as well as mutation type and heredity are shown. Bold characters
underline mutations not described elsewhere and italic characters indicate
silent point mutations. Nucleotides positions are marked with an n followed
by the position number. Transversion or transition mutation types are marked
by Tv or Ti respectively. Germline and somatic mutations are designated by g
and s respectively and correspond to mutations found (germline, g) or not
found (somatic, s, tumor specific) in peripheral blood-DNA of the same
patients. KRAS mutations located within the codon 12 (M 12) or 13 (M13) are
highlighted.
Table 3 Combination of wild type and mutated exon 20
sequence in codon 787 of the EGFR gene
WBC Tumor CAG
(WT)
CA G/A Polym’
het’
CAA Polym’
hom’
Total
CAG (WT) 25 2 2 39
CA G/A Polym’
het’
29 1 0 9 3
CAA Polym’
hom’
1 0 92 93
Total 38 93 94 225
Wild type (WT) and mutant (polymorphic heterozygous (polym het) or
homozygous (polym hom)) sequences of EGFR exon 20 codon 787 have been
found in tumors and peripheral blood-DNA (WBC: White Blood Cells).
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small number of somatic missense mutation (5 cases)
found in our study doesn’t allow us to get statistical sig-
nificant results but we can underline that none of these
patients showed mutations in K-ras whereas K-ras
mutation frequency in colorectal cancer vary from 30%
to 40%.
Moreover, the comparison of the mutational status
and clinical parameters which would have been of great
interest is not possible due to the small number of
somatic missense mutation (5 cases) found in our study.
A larger cohort would be needed to address these
questions.
Functional analysis would also be of great interest to
study the impact of the new mutations described in this
work on EGFR expression and signaling.
Conclusions
In conclusion, missense mutation, which may be respon-
sible for an activation of the EGFR gene through amino
acid substitution, seems not to play a major role in the
occurrence and development of colorectal cancer. How-
ever, the frequency of mutation in the population in our
study is much higher than in a similarly sized popula-
tion characterized by Barber and colleagues,[15] and
four new EGFR mutations were described.
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